Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT05538091 is registered in ClinicalTrials.gov with Ronald Buckanovich as lead sponsor.

NCT NCT05538091
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05538091 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Trial Combining the Hedgehog Inhibitor Vismodegib With the PD-L1 Inhibitor Atezolizumab in Patients With Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Lead sponsor
Ronald Buckanovich
Phase
Phase 2
Overall status
Recruiting
Start date
May 15, 2023
Completion date
September 30, 2032
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hedgehog inhibitor, parp inhibitor, platinum-resistant fallopian tube carcinoma, platinum-resistant primary peritoneal carcinoma